Search
Now showing items 1-10 of 35
Investigating the role of DTX3L in the replication stress response
(Institute of Cancer Research (University Of London), 2023-01-20)
DNA replication must be carried out with high fidelity to ensure accurate transfer of genetic information upon cell division. The mechanisms by which damage upon DNA is repaired are extensive and are increasingly well ...
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases.
(ELSEVIER, 2023-05-04)
BACKGROUND: COVID-19 has significantly affected patients with cancer and revealed unanticipated challenges in securing optimal cancer care across different disciplines. The European Society for Medical Oncology COVID-19 ...
Genomic markers in differentiated thyroid cancer
(Institute of Cancer Research (University Of London), 2023-06-14)
This thesis explores the potential use of genomic markers to assist the management of differentiated thyroid cancer (DTC) patients throughout the course of their treatment pathway. We explore the use of these markers to ...
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
(LIPPINCOTT WILLIAMS & WILKINS, 2023-04-20)
PURPOSE: CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus fluorouracil ≤ six cycles, then cetuximab ...
Vaccinia E5 is a major inhibitor of the DNA sensor cGAS.
(NATURE PORTFOLIO, 2023-05-22)
The DNA sensor cyclic GMP-AMP synthase (cGAS) is critical in host antiviral immunity. Vaccinia virus (VACV) is a large cytoplasmic DNA virus that belongs to the poxvirus family. How vaccinia virus antagonizes the cGAS-mediated ...
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
(ELSEVIER, 2023-03-01)
BACKGROUND: Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis. The phase III KESTREL study evaluated the efficacy of durvalumab [programmed death-ligand 1 (PD-L1) ...
Pathway choice in the alternative telomere lengthening in neoplasia is dictated by replication fork processing mediated by EXD2's nuclease activity.
(NATURE PORTFOLIO, 2023-04-27)
Telomerase-independent cancer proliferation via the alternative lengthening of telomeres (ALT) relies upon two distinct, largely uncharacterized, break-induced-replication (BIR) processes. How cancer cells initiate and ...
Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
(ELSEVIER SCI LTD, 2023-09-01)
For the past 2 decades, cisplatin-based adjuvant chemoradiotherapy (CRT) has remained the standard of care for patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) who are at ...
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
(BMJ PUBLISHING GROUP, 2023-01-01)
BACKGROUND: Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors. METHODS: Patients had advanced ...
Surgeon-led multi-centre collaborative research in head and neck cancer : studies in remote triage, transoral robotic surgery for recurrent disease and consensus management in unknown primary disease
(Institute of Cancer Research (University Of London), 2023-01-23)
Head and neck cancer (HNC) is newly diagnosed in around 1.5 million people each year, making it the sixth most common type of cancer worldwide. Some elements of HNC care are common and can be adequately investigated in a ...